218 results
6-K
EX-99.1
PPBT
Purple Biotech Ltd
2 May 24
Report of Foreign Private Issuer
4:13pm
provisions of the Private Securities Litigation Reform Act of 1995 . Such forward - looking statements include, but are not limited to, statements … decision or recover damages in any such action ; and the exposure to litigation, including patent litigation, and/or regulatory actions ; the impact
6-K
EX-99.1
PPBT
Purple Biotech Ltd
25 Apr 24
Purple Biotech’s Randomized Phase 2 CM24 Pancreatic Cancer Study Selected as Late-Breaking Abstract Poster Presentation at ASCO 2024 Annual Meeting
7:10am
of the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Such forward-looking statements include, but are not limited … ; and the exposure to litigation, including patent litigation, and/or regulatory actions; the impact of the economic, public health, political and security
POS AM
PPBT
Purple Biotech Ltd
28 Mar 24
Prospectus update (post-effective amendment)
4:01pm
or criteria;
reasonable litigation expenses, including reasonable attorneys’ fees, incurred by the office holder as a result of an investigation … )(a) to the Securities Law;
expenses associated with an Administrative Procedure conducted regarding an office holder, including reasonable litigation expenses
6-K
EX-99.1
PPBT
Purple Biotech Ltd
28 Mar 24
Purple Biotech to Present New Data On its Oncology Drug NT219 at AACR 2024
7:10am
Litigation Reform Act of 1995. Such forward-looking statements include, but are not limited to, statements that are not statements of historical fact … to litigation, including patent litigation, and/or regulatory actions; the impact of the economic, public health, political and security situation in Israel
6-K
EX-99.1
PPBT
Purple Biotech Ltd
14 Mar 24
Purple Biotech Reports Preclinical Proof of Concept for its Tribody Platform Technology
7:40am
-looking statements within the meaning of the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Such forward-looking … , obtain a favorable decision or recover damages in any such action; and the exposure to litigation, including patent litigation, and/or regulatory
6-K
EX-99.1
111f um1ftd
6 Mar 24
Report of Foreign Private Issuer
4:06pm
6-K
EX-99.1
s19 47rt9j0msye4z9
5 Mar 24
Purple Biotech Reports Fourth Quarter and Full-Year 2023 Financial Results
7:58am
6-K
EX-99.1
g672c63c
27 Feb 24
Purple Biotech Presents Data of its Phase 1 Head & Neck Cancer of NT219 in combination with Cetuximab at ESMO TAT Congress 2024
7:10am
6-K
EX-99.1
84m5o
13 Feb 24
Purple Biotech Convenes a Head & Neck Cancer Scientific Advisory Board in Preparation for NT219 Phase 2 Trial
7:10am
6-K
EX-99.1
jcvl8mbyp0f 1c
1 Feb 24
Report of Foreign Private Issuer
7:40am
6-K
EX-99.1
wh10rfdq504
20 Dec 23
Purple Biotech Appoints Dr. Yael Margolin to its Board of Directors
8:06am
6-K
EX-99.1
zuj3xo5hjzykq1
14 Dec 23
Purple Biotech Completes Patient Enrollment in Phase 2 Pancreatic Cancer Trial
7:00am
6-K
EX-99.1
ib9nkuf
21 Nov 23
Report of Foreign Private Issuer
4:00pm
6-K
EX-99.1
y8xhiy9nfrub
21 Nov 23
Purple Biotech Reports Third Quarter 2023 Financial Results
7:00am
F-1/A
gor1j
13 Nov 23
Registration statement (foreign) (amended)
4:11pm
6-K
EX-99.1
q4q4s4e61ra ait86j4h
2 Nov 23
Purple Biotech Fortifies NT219 Patent Protection
7:04am
F-1
7erm84 dnwdbyyhm
30 Oct 23
Registration statement (foreign)
4:30pm
6-K
EX-99.1
1ru 2jxxvyin6s1vjxew
19 Oct 23
Purple Biotech Announces Closing of $5 Million Registered Direct Offering
4:17pm
6-K
EX-4.1
8zbtr
19 Oct 23
Report of Foreign Private Issuer
10:36am